mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

被引：43

作者：

O'Regan, Ruth ^{[1
]}

Hawk, Natalyn Nicole ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

EXPERT OPINION ON THERAPEUTIC TARGETS | 2011年 / 15卷 / 07期

关键词：

breast cancer; everolimus; mTOR inhibitors; ridaforolimus; temsirolimus; GROWTH-FACTOR-I; ESTROGEN-RECEPTOR-ALPHA; MAMMALIAN TARGET; PHASE-I; PROGESTERONE-RECEPTOR; PROMOTER METHYLATION; POSTMENOPAUSAL WOMEN; LAPATINIB RESISTANCE; RAPAMYCIN PATHWAY; PTEN EXPRESSION;

D O I：

10.1517/14728222.2011.575362

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Areas covered: This review describes how dysregulation of the mTOR pathway in breast cancer may contribute to breast cancer pathogenesis, as well as discussing preclinical and clinical data that support mTOR inhibitor therapy. Expert opinion: Direct blockade of the mTOR pathway is a new and intriguing area in breast cancer therapy, with the potential to modulate growth-factor and estrogen-dependent and -independent pathways, that contribute to the pathogenesis and progression of breast tumors. mTOR inhibitors demonstrate significant biologic activity with manageable toxicities, in combination with hormonal therapy and chemotherapy, in both the neoadjuvant and metastatic breast cancer settings.

引用

页码：859 / 872

页数：14